Tissue factor, its pathway inhibitor, and metabolic disturbances in long-term peritoneal dialysis

Kidney and Blood Pressure Research

Volumn 26, Issue 5-6, 2003, Pages 368-375

  Zemanová, Pavlína ^a   Opatrný Jr , Karel ^a   Opatrná, Sylvie ^a   Vít, Ladislav ^a   Šefrna, František ^a   Racek, Jaroslav ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Diabetes mellitus; Peritoneal dialysis; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

THROMBOPLASTIN;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; METABOLIC DISORDER; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REGRESSION ANALYSIS;

ADULT; AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS; FEMALE; HEMOSTASIS; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS; MALE; METABOLIC DISEASES; MIDDLE AGED; PERITONEAL DIALYSIS; THROMBOPLASTIN; TIME FACTORS;

EID: 0344395123     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073944     Document Type: Article

References (36)

1. Morrissey JH: Tissue factor: An enzyme cofactor and a true receptor. Thromb Haemost 2001;86:66-74.
2. Broze GJ Jr: Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995;46:103-112.
3. Doshi SN, Marmur JD: Evolving role of tissue factor and its pathway inhibitor. Crit Care Med 2002;30:241-250.
4. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP: Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001;86:959-972.
5. Hansen JB, Huseby KR, Huseby NE, Ezban M, Nordoy A: Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro. Thromb Res 1997;85:413-425.
6. Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM: Tissue factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997;349:769-771.
7. Mann J, Davies MJ: Mechanisms of progression in native coronary artery disease: Role of healed plaque disruption. Heart 1999;82:265-268.
8. Saigo M, Abe S, Ogawa M, Yamashita T, Biro S, Minagoe S, Maruyama I, Tei C: Imbalance of plasminogen activator inhibitor-I/tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction. Thromb Haemost 2001;86:1197-1203.
9. Makin AJ, Chung NA, Silverman SH, Lip GY: Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: A link between angiogenesis and thrombogenesis? Clin Sci (Lond) 2003;104: 397-404.
10. Creasey AA, Reinhart K: Tissue factor pathway inhibitor activity in severe sepsis. Crit Care Med 2001;29:126-129.
11. Ott I, Malcouvier V, Schomig A, Neumann FJ: Proteolysis of tissue factor pathway inhibitor-1 by thrombolysis in acute myocardial infarction. Circulation 2002;105:279-281.
12. Rao LV: Tissue factor as a tumor procoagulant. Cancer Metastasis Rev 1992;11:249-246.
13. Yamani MH, Masri CS, Ratliff NB, Bond M, Starling RC, Tuzcu EM, McCarthy PM, Young JB: The role of vitronectin receptor (alphavbeta3) and tissue factor in the pathogenesis of transplant coronary vasculopathy. J Am Coll Cardiol 2002;39:804-810.
14. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS: Atherosclerotic cardiovascular disease risk in chronic hemodialysis patients. Kidney Int 2000;58:353-362.
15. Murphy BG, Hill CM, Middleton D, Doherty CC, Brown JH, Nelson WE, Kernohan RM, Keane PK, Douglas JF, McNamee PT: Increased renal allograft thrombosis in CAPD patients. Nephrol Dial Transplant 1994;9: 1166-1169.
16. Jones CL, Andrew M, Eddy A, O'Neil M, Shalom NI, Balfe JW: Coagulation abnormalities in chronic peritoneal dialysis. Pediatr Nephrol 1990;4:152-155.
17. Kannel WB, McGee DL: Diabetes and cardiovascular risk factors: The Framingham Study. Circulation 1979;59:8-13.
18. Kario K, Matsuo T, Yamada T, Matsuo M: Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis. Thromb Haemost 1994;71:275-279.
19. Cella G, Vertolli U, Naso A, Vianello A, Rampin E, Sbarai A, Boeri G, Strauss WE: Tissue factor pathway inhibitor (TFPI) activity in uremic patients during hemodialysis. Thromb Res 1996;81:671-677.
20. Reverter JL, Reverter JC, Tassies D, Rius F, Monteagudo J, Rubbies-Prat J, Escolar G, Ordinas A, Sanmarti A: Thrombomodulin and induced tissue factor expression on monocytes as markers of diabetic microangiopathy: A prospective study on hemostasis and lipoproteins in insulin-dependent diabetes mellitus. Am J Hematol 1997;56:93-99.
21. Ritz E, Rychlik I, Locatelli F, Halimi S: End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;34:795-808.
22. Borawski J, Naumnik B, Mysliwiec M: Tissue factor and thrombomodulin in hemodialysis patients: Association with endothelial injury, liver disease, and erythropoietin therapy. Clin Appl Thromb Hemost 2002;8:359-367.
23. Opatrný K Jr, Zemanová P, Mareš J, Vít L, Opatrná S, Šefrna F, Hejda V, Tomšù M, Eiselt J, Massry SG: Fibrinolysis defect in long-term hemodialysis patients with type 2 diabetes mellitus and its relation to metabolic disorders. Am J Nephrol 2002;22:429-436.
24. Malyszko J, Malyszko JS, Mysliwiec M: Tissue factor pathway inhibitor and tissue factor in HD and CAPD. Nephrol Dial Transplant 1998;13:2424-2426.
25. Al-Saady NM, Leatham EW, Gupta S, Kwan JT: Monocyte expression of tissue factor and adhesion molecules: The link with accelerated coronary artery disease in patients with chronic renal failure. Heart 1999;81:134-140.
26. Wanner C, Metzger T: C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant 2002;17(suppl 8):29-32.
27. Stenvinkel P, Heimburger O, Lindholm B, Kaysen GA, Bergstrom J: Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000;15:953-960.
28. Lowrie EG, Lew NL: Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:458-482.
29. Palmier MO, Hall LJ, Reisch CM, Baldwin MK, Wilson AG, Wun TC: Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thromb Haemost 1992;68:33-36.
30. Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, Boren J: Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417:750-754.
31. Sandset PM, Larsen ML, Abildgaard U: Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): Levels in the normal human population and relation to cholesterol. Blood Coagul Fibrinolysis 1991;2:425-433.
32. Matsuo T, Koide M, Kario K, Suzuki S, Matsuo M: Extrinsic coagulation factors and tissue factor pathway inhibitor in end-stage chronic renal failure. Haemostasis 1997;27:163-167.
33. Zumbach M, Hofmann M, Borcea V, Luther T, Kotzsch M, Müller M, Hergesell O, Andrassy K, Ritz E, Ziegler R, Wahl P, Nawroth PP: Tissue factor antigen is elevated in patients with microvascular complications of diabetes mellitus. Exp Clin Endocrinol Diabetes 1997;105: 206-212.
34. Son JW, Koh KK, Ahn JY, Jin DK, Park GS, Kim DS, Shin EK: Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int J Cardiol 2003;88:77-82.
35. Soejima H, Ogawa H, Yasie H, Kaikita K, Nishiyama K, Misumi K, Takazoe K, Miyao Y, Yoshimura M, Kugiyama K, Nakamura S, Tsuji I, Kumeda K: Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999;99:2908-2913.
36. Yorioka N, Taniguchi Y, Yamashita K, Ueda C, Nakamura C, Harada S, Yamakido M: Tissue factor and tissue factor pathway inhibitor in hemodialysis patients. Int J Artif Organs 1998;21:699-701.